Agenus Inc. (NASDAQ:AGEN) shares shot up 3.3% during trading on Wednesday . The company traded as high as $4.73 and last traded at $4.68, with a volume of 465,497 shares. The stock had previously closed at $4.53.

A number of research firms have recently commented on AGEN. Zacks Investment Research upgraded shares of Agenus from a “sell” rating to a “hold” rating in a report on Tuesday, July 5th. Maxim Group reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Agenus in a research note on Friday, June 10th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Agenus in a research note on Saturday, April 30th. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $10.47.

The stock’s market capitalization is $408.35 million. The company’s 50 day moving average is $4.29 and its 200-day moving average is $3.79.

Agenus (NASDAQ:AGEN) last issued its quarterly earnings data on Thursday, April 28th. The company reported ($0.37) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.23) by $0.14. On average, equities research analysts predict that Agenus Inc. will post ($1.36) EPS for the current year.

In other news, CEO Garo H. Armen acquired 100,000 shares of Agenus stock in a transaction on Monday, May 9th. The stock was bought at an average price of $3.18 per share, for a total transaction of $318,000.00. Following the completion of the purchase, the chief executive officer now owns 1,346,026 shares in the company, valued at $4,280,362.68. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Agenus Inc (Agenus) is an immunotherapy company. The Company is engaged in discovering and developing treatments for patients with cancer and other diseases. Its approaches are driven by three platform technologies: Its antibody platform, including Retrocyte Display technology, which is designed to produce human monoclonal antibodies focused on advancing checkpoint modulators (CPMs); its heat shock protein (HSP)-based vaccines, and its saponin-based vaccine adjuvants, QS-21 Stimulon adjuvant (QS-21 Stimulon).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.